None of the 29 investors followed here reported a position in PLSE in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PLSE trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 10, 2026 | Laviolette Paul AChief Executive Officer | Purchase at price 19.69 per share. | 15K | $295.35K |
| May 10, 2026 | Duggan Robert WilliamDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 19.69 per share. | 660.2K | $13.00M |
| May 10, 2026 | Duggan Robert WilliamDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 19.69 per share. | 660.2K | $13.00M |
| Feb 17, 2026 | Danahy Kevin PatrickOfficer | Sale at price 23.64 per share. | 5K | $118.20K |
| Feb 17, 2026 | Danahy Kevin PatrickOfficer | Conversion of Exercise of derivative security at price 1.53 per share. | 5K | $7.65K |
| Feb 16, 2026 | Danahy Kevin PatrickOfficer | Sale at price 23.37 - 23.63 per share. | 60K | $1.41M |
| Feb 16, 2026 | Danahy Kevin PatrickOfficer | Conversion of Exercise of derivative security at price 1.53 per share. | 60K | $91.80K |
| Feb 10, 2026 | Danahy Kevin PatrickOfficer | Sale at price 21.45 - 25.20 per share. | 60K | $1.40M |
| Feb 10, 2026 | Danahy Kevin PatrickOfficer | Conversion of Exercise of derivative security at price 1.53 per share. | 60K | $91.80K |
| Oct 1, 2025 | Danahy Kevin PatrickOfficer | Sale at price 18.53 per share. | 4.6K | $85.24K |
| Oct 1, 2025 | Danahy Kevin PatrickOfficer | Conversion of Exercise of derivative security at price 1.53 per share. | 4.6K | $7.04K |
| Sep 18, 2025 | Danahy Kevin PatrickOfficer | Sale at price 18.48 - 18.49 per share. | 20.4K | $377.19K |
| Sep 18, 2025 | Danahy Kevin PatrickOfficer | Conversion of Exercise of derivative security at price 1.53 per share. | 20.4K | $31.21K |
| Sep 16, 2025 | Uecker Darrin RChief Technology Officer | Sale at price 16.21 - 16.28 per share. | 45K | $731.20K |
| Sep 16, 2025 | Uecker Darrin RChief Technology Officer | Conversion of Exercise of derivative security at price 4.00 per share. | 206.5K | $826.14K |
| Sep 14, 2025 | Uecker Darrin RChief Technology Officer | Sale at price 14.32 - 15.77 per share. | 75K | $1.12M |
| Sep 14, 2025 | Uecker Darrin RChief Technology Officer | Conversion of Exercise of derivative security at price 4.00 per share. | 75K | $300.00K |
| Sep 9, 2025 | Duggan Robert WilliamDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 14.66 - 18.91 per share. | 192.6K | $3.44M |
| Jun 12, 2025 | Uecker Darrin RChief Technology Officer | Sale at price 15.98 - 16.40 per share. | 30K | $485.70K |
| Feb 2, 2025 | Zanganeh MahkamDirector | Conversion of Exercise of derivative security at price 11.00 per share. | 60.2K | $662.66K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.7 | 35.4 | 15.3 | -1.9 | 18.1 | 10.9 | 26.7 | 43.3 | -0.8 | 1.9 | +270.5% | ||
| 2025 | 20.2 | -12.5 | -12.1 | 5.8 | 1.7 | -12.8 | -0.5 | 3.5 | 13.9 | -4.4 | -19.1 | 0.3 | −21.1% |
| 2024 | -27.5 | 11.3 | -11.8 | -15.4 | 56.7 | -3.1 | 33.7 | 24.6 | -5.9 | -0.6 | 22.8 | -18.6 | +42.2% |
| 2023 | 13.0 | -12.8 | 23.1 | 91.7 | -3.7 | 16.0 | 9.9 | -40.4 | -14.4 | 12.2 | 99.8 | 35.5 | +341.9% |
| 2022 | -17.9 | -58.2 | -4.3 | -48.6 | -10.8 | -31.4 | 2.0 | -18.6 | 81.1 | -8.3 | -5.2 | 38.5 | −81.3% |
| 2021 | 43.1 | -14.3 | -19.0 | -18.7 | -6.3 | -9.1 | 25.0 | 26.3 | -16.6 | -2.4 | -3.7 | -27.0 | −37.9% |
| 2020 | 4.4 | -51.1 | 4.5 | 56.8 | -19.1 | 15.1 | -2.0 | -3.5 | 19.2 | 2.7 | 23.0 | 60.1 | +77.9% |
| 2019 | 16.6 | 33.5 | -1.3 | -8.9 | -25.5 | 10.6 | -1.1 | -8.2 | 28.8 | -8.8 | 3.1 | -7.6 | +17.0% |
| 2018 | -14.1 | -8.8 | -26.9 | 30.0 | -10.2 | -4.1 | -11.8 | 7.5 | -1.2 | -9.7 | -2.1 | -8.6 | −51.4% |
| 2017 | 0.8 | 105.2 | 51.9 | 18.2 | 18.5 | 20.8 | -43.7 | 3.1 | -7.1 | 30.1 | -10.8 | 9.3 | +263.1% |
| 2016 | 4.7 | 1.8 | 7.7 | 27.8 | -2.7 | 0.2 | 6.0 | +51.5% |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Buy / hold / sell counts